Literature DB >> 1097148

Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol.

L E Hollister, H Gillespie.   

Abstract

Oral doses of delta-9-tetrahydrocannabinol (THC) 20 mg, combined with placebo or with 40 mg dses of cannabinol (CBN) and cannabidiol (CBD), were given to volunteers. The combination of THC with CBN produced no detectable changes in the quality, intensity, or duration of the effects of THC alone. The THC-CBD combination tended to delay onset and prolong effects of THC, while making them somewhat more intense. Even this interactive effect was slight, providing no reason to abandon the current practice of basing doses of marihuana for clinical studies solely on THC content.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1097148     DOI: 10.1002/cpt197518180

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

1.  Subjective and physiological effects after controlled Sativex and oral THC administration.

Authors:  E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

Review 2.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

3.  Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Authors:  Charlotte Klein; Emily Karanges; Adena Spiro; Alexander Wong; Jarrah Spencer; Thanh Huynh; Nathan Gunasekaran; Tim Karl; Leonora E Long; Xu-Feng Huang; Kelly Liu; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2011-06-11       Impact factor: 4.530

4.  Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography.

Authors:  S Agurell; S Carlsson; J E Lindgren; A Ohlsson; H Gillespie; L Hollister
Journal:  Experientia       Date:  1981-10-15

5.  Intercannabinoid and cannabinoid-ethanol interactions on human performance.

Authors:  K D Bird; T Boleyn; G B Chesher; D M Jackson; G A Starmer; R K Teo
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

6.  The pharmacological effect of fractions obtained by smoking cannabis through a water-pipe. II. A second fractionation step.

Authors:  H Lazaratou; A Moschovakis; A Armaganidis; V Kapsambelis; J Kiburis; T A Kephalas
Journal:  Experientia       Date:  1980-12-15

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

9.  The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys.

Authors:  K T Brady; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

10.  Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.

Authors:  A W Zuardi; I Shirakawa; E Finkelfarb; I G Karniol
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.